Xencor | XNCR - Betriebsaufwand





Betriebsaufwand Veränderung Datum
AbbVie USD 10.27B 538M 2026-03
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
Amgen USD 4.78B 1.12B 2026-03
Arrowhead Research USD 223.22M 10.86M 2025-12
AstraZeneca USD 8.18B 4.35B 2026-03
Biogen USD 1.96B 69.6M 2026-03
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Cytokinetics USD 196.12M 27.43M 2025-12
GlaxoSmithKline GBP 5.34B 1.85B 2026-03
J&J USD 17.44B 1.53B 2026-03
Karyopharm Therapeutics USD 51.92M 9.9M 2025-12
MacroGenics USD 53.32M 13.68M 2025-12
Merck USD 18.17B 8.01B 2026-03
Novartis USD 9.29B 507M 2026-03
Pfizer USD 90.1B 77.19B 2026-03
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Roche Holding CHF 21.01B 10.84B 2025-12
Xencor USD 81.86M 13.35M 2025-12